PHAR (PHAR) Stock Price & Analysis
PHAR (PHAR) fell 1.64% to USD 12.59 as of June 10, 2026 at 05:50 UTC, according to Nexqual real-time market data.
PHAR last closed at USD 12.8; the session ranged USD 12.32–12.72 on volume of 4,066 shares. Market capitalization is $889.17M, with a 52-week range of USD 9.54–21.34 (NGM). Source: Nexqual, June 10, 2026 at 05:50 UTC.
Key Statistics (as of June 10, 2026 at 05:50 UTC)
| Price | USD 12.59 |
|---|---|
| Change | ▼ 1.64% (down) |
| Previous Close | USD 12.8 |
| Open | USD 12.72 |
| Day Range | USD 12.32 – 12.72 |
| 52-Week Range | USD 9.54 – 21.34 |
| Volume | 4,066 shares |
| Market Cap | $889.17M |
| Exchange | NGM |
Technical Analysis (PHAR)
Nexqual's technical model rates PHAR "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:50 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.5 (neutral) |
| vs SMA50 | Below (USD 15.06) |
| MACD | -0.66 (negative) |
Analyst Ratings (PHAR)
Wall Street analysts rate PHAR "Strong Buy" based on 4 analysts, with a mean price target of USD 34.35 (range USD 23.4–40), per Nexqual as of June 10, 2026 at 05:50 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 34.35 |
| High Target | USD 40 |
| Low Target | USD 23.4 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (PHAR)
| EPS Estimate | USD 0.06 |
|---|---|
| Revenue Estimate | $101.28M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.07 vs est 0 ▼ miss |
| 2025-12-31 | USD 0.07 vs est 0.01 ▲ beat |
| 2025-09-30 | USD 0.01 vs est 0 ▲ beat |
| 2025-06-30 | USD 0.01 vs est -0.01 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:50 UTC.
Financials & Fundamentals (PHAR)
| Total Revenue | $369.49M |
|---|---|
| Revenue Growth (YoY) | -8.40% |
| Gross Margin | +88.14% |
| Operating Margin | -6.78% |
| Profit Margin | +3.34% |
| ROE | +5.04% |
| Debt / Equity | 43.21 |
| Current Ratio | 2.63 |
| Total Cash | $170.18M |
| Total Debt | $116.20M |
| Free Cash Flow | $59.02M |
Source: Nexqual, June 10, 2026 at 05:50 UTC.
Financial Health Score (PHAR)
Nexqual rates PHAR's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 05:50 UTC.
| Growth | Strong — Revenue +27% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 88%, operating -7% |
| Balance Sheet | Strong — $170M cash vs $116M debt, net cash position |
| Cash Flow | Strong — FCF $59M, 16% margin |
| Efficiency | Mixed — ROE 5%, ROA 4.9% |
Ownership (PHAR)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.15% |
| Shares Outstanding | 70.63M |
| Float | 73.29M |
| Short % of Float | +0.01% |
Source: Nexqual, June 10, 2026 at 05:50 UTC.
Leadership (PHAR)
PHAR is led by Fabrice Chouraqui M.B.A., Ph.D., Pharm.D., CEO & Executive Director, per Nexqual as of June 10, 2026 at 05:50 UTC.
| CEO & Executive Director | Fabrice Chouraqui M.B.A., Ph.D., Pharm.D. |
|---|---|
| Chief Financial Officer | Kenneth Lynard EMBA, M.Sc. (age 57) |
| Medical Director | Magnus Hansson (age 49) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHVS | Pharvaris N.V. | USD 31.6 | ▲ 1.64% |
| NBTX | Nanobiotix S.A. | USD 34.34 | ▼ 3.16% |
| PRTCY | PureTech Health PLC | USD 16.43 | ▼ 2.56% |
| SLN | Silence Therapeutics Plc - Amer | USD 6.01 | ▼ 2.59% |
| IVA | Inventiva S.A. - American Depos | USD 3.97 | ▼ 1.49% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:50 UTC. This page is informational and not investment advice.